Kezar Life Sciences preliminarily estimates $201.4M cash, 72.8M shares as of Dec 31, 2023

Kezar Life Sciences, Inc.

Preliminary cash, cash equivalents and marketable securities of approximately $201.4 million as of December 31, 2023.
Common stock outstanding estimated at 72.8 million shares as of December 31, 2023.
Estimates are unaudited and may change after completion of year-end closing and auditing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.